On 10 January 2018, the Shanghai Fosun Pharmaceutical (Group) Co. Ltd. Board agreed the proposal that the Company's subsidiary Fosun Pharma USA and Fosun International jointly establish the New Company, pursuant to which Fosun Pharma USA intends to contribute USD 25.50 million in cash, representing 51% interest therein, and Fosun International intends to contribute USD 24.50 million in cash, representing 49% interest therein. The principal terms for the Establishment of New Company. Upon the completion of the Establishment of New Company, it will focus on the overseas business in relation to R&D, manufacturing, medical devices and medical diagnosis, especially on the development and exploration of innovation.